REDWOOD CITY, Calif. – February 25, 2019 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the retirement of Susan Berland, Executive Vice President and Chief Financial Officer (CFO), and the appointment of Herb Cross, an accomplished senior financial executive, as her successor.

“Susan has been an invaluable part of the leadership team, and her expertise and financial stewardship have been instrumental to our success,” said John Orwin, President and CEO of Atreca. “We wish Susan all the best in her retirement, and she has graciously agreed to serve as a consultant to the Company. At the same time, we would also like to welcome her successor, Herb Cross, a seasoned financial executive who is well equipped to help us navigate the next phase of the Company’s growth as our lead asset progresses into clinical development.”

Mr. Cross brings more than 20 years of experience in financial leadership roles at both private and public biotechnology companies. Before joining Atreca, he was the first CFO at ARMO BioSciences, leading its initial public offering and serving in that role through the sale of the company to Eli Lilly in 2018. Prior to this, he was the CFO at Balance Therapeutics, leading the finance, investor relations, information technology, and other administrative functions. Previously, Mr. Cross was CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals, where he was responsible for overall strategic leadership and led the finance and administrative functions. He also served as CFO at Affymax. Earlier in his career, Mr. Cross was Vice President, Finance at Facet Biotech Corporation, a spin-off of PDL BioPharma, where he was Executive Director, Finance and Corporate Controller. Mr. Cross was also the Vice President of Finance for Neoforma and began his career at Arthur Andersen, LLP.

Mr. Cross received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

“With Atreca poised to move its lead therapeutic candidate into the clinic, a product of the Company’s proprietary and unique discovery platform, this is a very exciting time to join the company,” said Herb Cross, Chief Financial Officer of Atreca. “I am looking forward to working with the leadership team to continue building a pipeline of exciting programs.”

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics based on a deep understanding of the human immune response. We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.

Contact

Atreca, Inc.

Herb Cross

Chief Financial Officer

info@atreca.com

or

Media:

Nancie Steinberg, 212-213-0006, ext. 318

nsteinberg@burnsmc.com

Robert Flamm, 212-213-0006, ext. 364

rflamm@burnsmc.com

or

Investors:

Alex Gray, 212-213-0006, ext. 355

agray@burnsmc.com

Source: Atreca, Inc.